Theraclone Sciences is a Seattle-based, discovery-stage biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease, inflammation and cancer. The company's technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the I-STAR™ discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Looking for a particular Theraclone Sciences employee's phone or email?
Theraclone Sciences Questions
The Theraclone Sciences annual revenue was $11 million in 2026.
Theraclone Sciences is based in Seattle, Washington.
The NAICS codes for Theraclone Sciences are [5417, 541713, 54, 54171, 541].
The SIC codes for Theraclone Sciences are [87, 873].
Related Companies
